- Home
- CANF vs JXG Comparison
CANF vs JXG Comparison
Compare CANF & JXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- JXG
- Stock Information
- Founded
- CANF 1994
- JXG N/A
- Country
- CANF Israel
- JXG China
- Employees
- CANF N/A
- JXG N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- JXG
- Sector
- CANF Health Care
- JXG
- Exchange
- CANF Nasdaq
- JXG Nasdaq
- Market Cap
- CANF 9.6M
- JXG 10.4M
- IPO Year
- CANF N/A
- JXG N/A
- Fundamental
- Price
- CANF $0.59
- JXG $0.85
- Analyst Decision
- CANF Strong Buy
- JXG
- Analyst Count
- CANF 2
- JXG 0
- Target Price
- CANF $14.50
- JXG N/A
- AVG Volume (30 Days)
- CANF 174.9K
- JXG 1.8M
- Earning Date
- CANF 11-27-2025
- JXG 05-15-2025
- Dividend Yield
- CANF N/A
- JXG N/A
- EPS Growth
- CANF N/A
- JXG N/A
- EPS
- CANF N/A
- JXG 0.86
- Revenue
- CANF $560,000.00
- JXG $49,840,288.00
- Revenue This Year
- CANF $461.72
- JXG N/A
- Revenue Next Year
- CANF N/A
- JXG N/A
- P/E Ratio
- CANF N/A
- JXG $0.99
- Revenue Growth
- CANF N/A
- JXG 56.53
- 52 Week Low
- CANF $0.59
- JXG $0.55
- 52 Week High
- CANF $3.12
- JXG $7.72
- Technical
- Relative Strength Index (RSI)
- CANF 32.24
- JXG 44.48
- Support Level
- CANF $0.60
- JXG $0.83
- Resistance Level
- CANF $0.64
- JXG $0.90
- Average True Range (ATR)
- CANF 0.03
- JXG 0.10
- MACD
- CANF 0.00
- JXG 0.01
- Stochastic Oscillator
- CANF 2.03
- JXG 39.09
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.